mesalamine and omeprazole

mesalamine has been researched along with omeprazole in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's6 (60.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ajjan, RA; Hussain, FN; Moustafa, M; Riley, SA; Weir, NW1
Miehsler, W; Oberhuber, T; Püspök, A; Vogelsang, H1
Calafat, AM; Hauser, R; Hernández-Díaz, S; Kelley, KE; Mitchell, AA1
Calafat, AM; Hauser, R; Hernández-Díaz, S; Kelley, KE; Mitchell, AA; Su, YC1

Reviews

1 review(s) available for mesalamine and omeprazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for mesalamine and omeprazole

ArticleYear
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
    Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21

    Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship

2003
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.
    British journal of clinical pharmacology, 1998, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Anti-Ulcer Agents; Delayed-Action Preparations; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Lactulose; Mesalamine; Middle Aged; Omeprazole; Proton Pump Inhibitors

1998
Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract.
    Inflammatory bowel diseases, 2001, Volume: 7, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Crohn Disease; Data Interpretation, Statistical; Disaccharides; Duodenal Diseases; Esophageal Diseases; Famotidine; Female; Humans; Lansoprazole; Male; Mannitol; Mesalamine; Middle Aged; Omeprazole; Permeability; Proton Pumps; Retrospective Studies; Stomach Diseases; Treatment Outcome

2001
Medications as a potential source of exposure to phthalates in the U.S. population.
    Environmental health perspectives, 2009, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Data Collection; Didanosine; Environmental Exposure; Female; Humans; Male; Mesalamine; Middle Aged; Omeprazole; Pharmaceutical Preparations; Phthalic Acids; Pregnancy; Theophylline; Young Adult

2009
Medications as a potential source of exposure to phthalates among women of childbearing age.
    Reproductive toxicology (Elmsford, N.Y.), 2013, Volume: 37

    Topics: Adolescent; Adult; Amitriptyline; Drug Utilization; Environmental Exposure; Female; Humans; Mesalamine; Middle Aged; Omeprazole; Phthalic Acids; Pregnancy; Young Adult

2013